Table 1 Summary of studies included for which data was received
Study acronym | Study | Study drug | Comparator drug | Sponsor | Design | Study duration (weeks) | Number of arms | Participants | Percentage of women | Mean age of participants (SD) |
|---|---|---|---|---|---|---|---|---|---|---|
ENDURANCE-4 | Asselah, 2018 [36] | Glecaprevir/pibrentasvir | NA | AbbVie Deutschland GmbH & Co. KG | Non-controlled cohort study | 24 | 1 | 121 | 36.4 | 52.66 (11) |
M41008−1002, | Mrowietz, 2017 [37] | Dimethyl fumarate | Placebo/dimethyl fumarate + ethyl hydrogen fumarate | Almirall, S.A. | Superiority and non-inferiority (head to head) | 16 | 3 | 699 | 35.3 | 44.2 (14.5) |
ERC 231 | Archer, 2015 [38] | Dehydroepiandrosterone (DHEA) | Placebo | Endoceutics | Superiority (head to head) | 12 | 3 | 255 | 100 | 58.5 (6) |
Clarity | Giovannoni, 2010 [39] | Cladribine | Placebo | Merck Serono International S.A. | Superiority (head to head) | 96 | 3 | 1326 | 67.6 | 38.6 (10) |
NN7088-3885 | Trakymiene, 2020 [40] | Turoctocog Alfa pegol | NA | Novo Nordisk A/S | Non-controlled cohort study | 26 | 1 | 68 | 0 | 6 (3.3) |
SUSTAIN 2 | Ahren, 2017 [41] | Semaglutide | Sitagliptine | Novo Nordisk A/S | Superiority and non-inferiority (head to head) | 56 | 4 | 1231 | 49.4 | 55.1 (10) |
SUSTAIN 5 | Rodbard, 2018 [42] | Semaglutide | Placebo | Novo Nordisk A/S | Superiority (head to head) | 30 | 4 | 397 | 43.9 | 58.8 (10.1) |
TRANSFORM-1 | Fedgchin, 2019 [43] | Esketamine | Placebo | Janssen-Cilag International NV | Superiority (head to head) | 4 | 3 | 346 | 70.3 | 46.3 (11.6) |
SUSTAIN-1 | Daly, 2019 [45] | Esketamine | Placebo | Janssen-Cilag International NV | Superiority (head to head) | 16 | 2 | 705 | 64.8 | 46.1 (11.1) |
SUSTAIN-2 | Wajs, 2020 [44] | Esketamine | NA | Janssen-Cilag International NV | Non-controlled cohort study | 52 | 1 | 802 | 62.6 | 52.2 (13.7) |